 cohort trials:
Cohort 1 people who had an adequate single segment
great saphenous vein (GSV) available for use as a bypass
conduit, and Cohort 2 people without an adequate single segment GSV who required an alternate conduit.
Treatment with a GSV bypass ﬁrst approach was superior
to endovascular therapy ﬁrst for the primary outcome
(hazard ratio [HR], 0.68; 95% conﬁd